Valencia Technologies announced 6-month interim efficacy data from its eCoin Pivotal Clinical Trial. The announcement follows the podium presentation of the interim data at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2020 Annual Meeting on February 28th, 2020.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
